June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Intravitreal dexamethasone implant for macular edema secondary to vitrectomy for epiretinal membrane
Author Affiliations & Notes
  • Carlos A Abdala
    Retina & Vitreous, Unidad Laser Clinica Oftalmologica, Barranquilla, Colombia
  • Melvin Cabreja
    Retina & Vitreous, Unidad Laser Clinica Oftalmologica, Barranquilla, Colombia
  • Maria A. Izquierdo
    Retina & Vitreous, Unidad Laser Clinica Oftalmologica, Barranquilla, Colombia
  • Footnotes
    Commercial Relationships Carlos Abdala, None; Melvin Cabreja, None; Maria Izquierdo, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 388. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Carlos A Abdala, Melvin Cabreja, Maria A. Izquierdo; Intravitreal dexamethasone implant for macular edema secondary to vitrectomy for epiretinal membrane. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):388.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To report the efficacy of 0.7 mg dexamethasone intravitreal implant in vitrectomized eyes with refractory macular edema secondary to combined vitrectomy with epiretinal membrane removal and phacoemulsification with IOL implantation.

 
Methods
 

We report a cases series of 12 eyes with refractory macular edema secondary to combined 23-gauge vitrectomy for epiretinal membrane removal with internal limiting membrane peeling without dying and cataract extraction with IOL implantation. These patients were previously treated for 3 months with NSAIDs, topical corticosteroid and periocular corticosteroid injections and the injection of the 0.7 mg dexamethasone implant was performed if macular edema persisted despite topical treatment. Best-corrected visual acuity, central retinal thickness measured by CIRRUS spectral domain optical coherence tomography, fundus examination and intraocular pressure were evaluated at baseline, 1 month, 2, 3 and 6 months. Cases of ERM secondary to other pathologies (retinal and choroid inflammation, vascular occlusion, ocular trauma, diabetes mellitus, retinal detachment, severe myopia, uveitis,) and age macular degeneration were excluded from the study.

 
Results
 

After a mean follow-up of 6.09 ± 0.71 months, mean best-corrected visual acuity was significantly increased (p: 0.003) from 20/100 to 20/50 , mean central retinal thickness decreased from 391 ± 54.5 mc to 335 ± 49.32 mc (p: 0.000), and mean intraocular pressure changed (p: 0.000) from 12.5 ± 1.06 to 16.7 ± 3.01 In no case postoperative complication was observed.

 
Conclusions
 

Injection of dexamethasone intravitreal implant resulted effective in the treatment of refractory macular edema secondary to combined cataract extraction and vitrectomy for macular epiretinal membrane removal.  

 

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×